FinWiki
日EN中

Synthetic securitisation in Japan — bank RWA relief via CLN / CDS on reference loan portfolios

Confidence: Likely Updated 2026-05-25 Review by 2026-11-25 Sources 5 Machine-translated Original (JA)
#structured-finance#synthetic#cln#cds#rwa#basel
On this page

TL;DR

Synthetic securitisation — where a bank transfers credit risk on a reference loan portfolio to outside investors via a credit-default swap (CDS) or credit-linked note (CLN) structure without selling the underlying loans — is the modern Basel III tool for risk-weighted asset (RWA) relief on bank balance sheets. In Japan, the three megabanks (MUFG, SMFG, Mizuho FG) have used synthetic securitisations selectively to free capital on corporate-loan, project-finance, and infrastructure-finance portfolios. Compared to European peer-bank deal flow, Japanese megabank synthetic-SRT (Significant Risk Transfer) issuance has been smaller and less frequent — Japanese banks historically have had ample capital buffers and have only intermittently needed RWA-relief deals. Investor base is dominated by global specialist credit-investor funds (hedge funds, structured-credit funds, some pension funds), which can absorb the junior or mezzanine risk-transfer tranches. FSA capital-relief approval requires the deal to demonstrate true credit-risk transfer under specific accounting and capital tests.

Wiki route

This entry sits under structured-finance index as the bank-capital-management securitisation node. Read against Japan ABS market overview (true-sale ABS as the alternative to synthetic), TK / GK SPV vehicle for the legal structure layer, and Japan CDS market overview for the underlying credit-derivative infrastructure. System frame: finance index for the broader bank-capital context, and institution anchors: MUFG, SMFG, Mizuho FG.

1. The problem — bank capital constraints on loan growth

Under Basel III rules, banks must hold regulatory capital against the credit risk of their loan book:

  • Corporate loans typically carry 50–100%+ risk-weight (varying by borrower rating)
  • Capital ratios (CET1, Tier 1, Total) set the maximum leverage
  • High-quality loans to lower-rated borrowers consume more capital than higher-rated borrowers

For a megabank seeking to grow lending volume in a particular sector or geography (e.g., project-finance lending into infrastructure, leveraged-finance corporate loans, or trade finance into emerging markets), the RWA constraint can bite before the funding constraint.

2. The two paths to RWA relief

PathMechanismTrade-off
True-sale securitisationSell the underlying loans to an SPV; loans leave the balance sheetCustomer-relationship implications; servicing handover; possible accounting/disclosure complexity
Synthetic securitisationKeep loans on balance sheet; transfer credit risk only via CDS / CLNCustomer relationship preserved; simpler operational handover; but capital relief depends on regulatory approval of risk transfer

For most large bank-customer relationships (where the bank wants to keep the relationship live for future lending, advisory, and cross-sell), synthetic securitisation is preferred — it relieves capital while preserving the customer-facing loan.

3. Synthetic securitisation structure

+---------------------------------+
|       Originating bank          |
|  - Holds reference loan         |
|     portfolio on balance sheet  |
|  - Pays protection premium      |
+----+----------------------+----+
     |                      |
   CDS/CLN              Capital relief
   protection           (FSA-approved
   premium              SRT)
     |                      
     v                      
+----+----------------------------+
|   Protection-selling SPV       |
|    or direct investor          |
|  - Funds collateral by issuing |
|     CLN tranches to investors  |
|  - Bears reference-portfolio    |
|     credit loss up to defined   |
|     attachment point            |
+----+----------------------+----+
     |                      |
   Junior tranche       Senior tranche
   (first-loss to        (higher loss
    investor)            attachment)
     |                      |
     v                      v
+----+-------+    +---------+--------+
|Specialist  |    |Pension /         |
|credit fund |    |insurer / less    |
|(hedge fund)|    |risk-tolerant inv |
+------------+    +------------------+

Key structural elements:

  • Reference portfolio: a defined pool of bank loans (e.g., 100–300 named corporate borrowers, or a portfolio of project-finance loans, or a thematic basket like trade-finance loans)
  • Tranching: typically a junior / first-loss tranche (most expensive protection but greatest capital-relief benefit), a mezzanine tranche, and a senior tranche (often retained by the bank or sold to lower-risk investors)
  • Funded vs unfunded: CLN is “funded” (investor pays cash up-front; SPV holds collateral); CDS can be “unfunded” (bilateral; counterparty-credit-risk considerations apply)
  • Tenor: typically 5–7 years matching average loan-portfolio life
  • Reference obligations: usually a static pool, sometimes a replenishable pool

4. FSA capital-relief approval — the structural test

For the originating bank to count synthetic securitisation as true risk transfer (and thus take RWA reduction), the deal must satisfy regulatory tests:

  • Significant Risk Transfer (SRT) requirement — meaningful credit risk must have moved off the bank’s balance sheet
  • The bank must not retain disproportionate retained tranche / first-loss
  • The protection seller (SPV / counterparty) must be reliable for the protection it sells
  • Accounting treatment must reflect the risk-transfer (or there must be specific Basel-allowed deconsolidation treatment)

The FSA reviews each deal individually for SRT compliance. This is a meaningful structuring friction — deals that work in EU markets may need adjustment for Japanese approval.

5. Japanese megabank synthetic-SRT activity

Japanese megabank synthetic-SRT issuance has been smaller and less frequent than European peer-bank flow:

  • European banks (BNP Paribas, Deutsche Bank, Santander, Crédit Agricole, Barclays, others) have been heavy users of synthetic-SRT for over a decade, with frequent multi-billion-euro deals
  • Japanese megabanks have used synthetic structures more selectively, partly because:
    • Capital ratios have been comfortably above regulatory minimums
    • Loan growth has been moderate, not requiring constant capital-relief deal flow
    • Cultural / relationship factors favour retaining loans visibly on the balance sheet
  • When megabanks have issued synthetic-SRT deals, the reference portfolios have tended to be project-finance loans, infrastructure loans, leveraged-finance corporate loans, or specific geographic-exposure books rather than core domestic-corporate lending

The market has been growing in recent years as Basel finalisation (Basel III/IV, output floor) increases capital pressure even on well-capitalised banks.

6. Investor base

The protection-seller side is dominated by:

  • Specialist credit-investor funds (hedge funds, structured-credit funds, dedicated SRT-investor funds)
  • Pension funds and insurers (some) for the more senior tranches
  • Sovereign wealth funds for selected large-ticket transactions
  • Fund-of-funds vehicles aggregating investor commitments

Japanese investor base for synthetic-SRT is small — most investors are global firms with US / EU teams that book SRT transactions from offices in London, NY, or Hong Kong.

7. Comparison to true-sale ABS

DimensionTrue-sale ABSSynthetic securitisation
Loan ownershipTransferred to SPVRetained by bank
Customer relationshipServicer-managed (often back to originating bank)Fully retained
Capital reliefFull (loan off balance sheet)Partial (RWA reduction)
FundingYes (cash from sale)None (or partial via funded CLN structure)
Operational complexityHigher (loan transfer, servicer handover)Lower (no loan transfer)
Investor baseBanks, insurers, broad fixed-incomeSpecialist credit funds (often US / EU)
Tax / accountingTrue-sale accountingDerivative-based accounting
Typical useFunding + capitalCapital-only

For pure RWA management on a relationship-sensitive corporate loan book, synthetic is the clear choice. For funding diversification on a granular consumer loan book, true-sale is the clear choice.

8. Recent illustrative themes (descriptive only)

Without naming specific transactions, recent themes in Japanese megabank synthetic-securitisation issuance include:

  • Project-finance and infrastructure-loan portfolios — useful because these loans are large-ticket and capital-intensive
  • Leveraged-finance corporate loan portfolios — capital-intensive, with cyclical credit exposure that fund investors are willing to take
  • Cross-border trade-finance portfolios — often regulatory-capital-driven for political-risk-weighted lending
  • ESG-linked variants — emerging interest in structures tied to sustainability metrics

The pace of new issuance has been increasing as Basel finalisation effective dates approach.

9. Counterpoints

  • “Regulatory-capital arbitrage” — Critics argue synthetic-SRT can be used to optimise reported capital ratios without materially changing the bank’s risk profile if the retained portions and first-loss positions are structured to flatter regulatory ratios
  • “Concentration in specialist investors” — The SRT-investor base is small; if global SRT-investor capital tightens, Japanese megabanks may struggle to place new issuance economically
  • “FSA approval friction” — The case-by-case SRT-approval process creates execution uncertainty; deals can be re-structured during approval, affecting economics
  • “Counterparty-credit risk on unfunded structures” — Unfunded CDS structures expose the bank to credit risk on the protection-seller; funded CLN structures avoid this but require larger investor capital
  • “Tail-risk transfer questioned” — In severe credit stress, whether the SPV / fund counterparty can actually pay claims is a real concern; AIG-style protection-seller failure is the classic example
  • “Limited public disclosure” — Synthetic-SRT deals are often not publicly announced or are described in deliberately vague terms in Pillar 3 disclosures, making market analysis difficult

10. Open questions

  • The pace of Japanese megabank synthetic-SRT issuance under Basel finalisation pressure (output-floor effective dates, etc.)
  • Whether Japan Post Bank or large regional banks issue synthetic-SRT (so far the activity is concentrated in the megabanks)
  • Whether the FSA approval process becomes more standardised over time, reducing structuring friction
  • Whether Japanese institutional investors (life insurers, pension funds) develop appetite for the senior tranches of synthetic-SRT deals
  • The interaction between synthetic-SRT and aircraft / ship / project-finance loan books — capital-intensive specialty loan portfolios are natural candidates
  • The treatment of ESG-linked synthetic-SRT structures and whether they gain regulatory or investor-demand traction

Sources

[!info] Review status confidence: likely. Synthetic-SRT mechanics, Basel-rule requirements, and Japanese-megabank relative activity vs European peers are well-documented in BIS papers and bank IR disclosures. Specific Japanese-megabank transactions are abstracted because public disclosure is often deliberately vague at the deal level. The European-peer comparison is industry-standard discussion.